Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 426

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 426
---
ateral”), and all obligations under the Amended and Restated Security Agreement (as defined therein) will be secured by the Royalty Collateral and second priority liens on the
collaterals under the ZTlido Royalty Security Agreement.

The foregoing summary of the ZTlido Subordination Agreement does not purport to
be complete and is qualified in its entirety by reference to the full text of the ZTlido Subordination Agreement, a copy of which is filed as an exhibit the registration statement of which this prospectus forms a part.

Oramed Note Consent and Amendment

In connection with the refinancing, we entered into a Consent and Amendment for the Oramed Note (the “Consent and Amendment”),
dated as of October 8, 2024 with Oramed. Pursuant to the Consent and Amendment, we and Oramed consent to (i) our Company’s (and, to the extent applicable, our subsidiaries’) entry into and performance of the Tranche B
Securities Purchase Agreement, the issuance of the Tranche B Notes and the October 2024 Noteholder Warrants and performance of the terms thereof, the entry into and performance of the ZTlido Royalty Purchase Agreement and other related amendment
documents and the consummation of the refinancing, (ii) modifications to certain defined terms under the Oramed Note, and (iii) the payment of all transaction fees and expenses related to the refinancing transactions. Oramed further agreed
that the proceeds of the refinancing transactions utilized to repay the Oramed Note shall not constitute a voluntary prepayment, and no Make-Whole Amount (as defined in the Oramed Note) or other premium shall be payable with respect thereto.

The foregoing summary of the Consent and Amendment does not purport to be complete and is qualified in its entirety by reference to the full
text of the Consent and Amendment, a copy of which is filed as an exhibit to the registration statement of which this prospectus forms a part.

278

Deferral and Consent under Tranche B Senior Secured Convertible Note

Pursuant to the Notes, commencing on January 2, 2025 (the “First Amortization Payment Date”), we are required to make the
First Amortization Payment to redeem in cash such portion of the principal amount of the Notes equal to the Holder Pro Rata Amount (as defined in the Notes) of each Tranche B Noteholder of $6,250,000